Israel’s BiondVax has 12,400 participants from 83 hospitals in the Phase 3 double-blind placebo-controlled trials of its Universal Flu vaccine. If successful, the new vaccine could reach pharmacies in 2023. BiondVax’s new Jerusalem facility can produce 20-40 million doses per … Continue reading →

Final results of BiondVax’s Phase 2b trials of its Universal Flu vaccine confirmed preliminary results reported here previously. (5 Feb) Both endpoints were met. Immune response to the vaccine was statistically significant. BiondVax can now proceed to Phase 3 final … Continue reading →

Israeli biotech Biondvax is to receive a Government grant for 20% of the NIS 20 million required to build a Jerusalem factory for commercial scale production of its M-001 Universal Flu vaccine.  Biondvax plans to produce tens of millions of … Continue reading →

Knowing many sufferers of the current flu bout, it is timely to report positive preliminary results in the Phase 2b trials of the Universal Flu vaccine from Israel’s BiondVax.  And thanks to a $2.8 million investment (see Jan 15), BiondVax … Continue reading →

Preliminary results from the Phase 2 clinical trials of Universal Flu vaccine M-001 from Israel’s BiondVax have shown the treatment to be effective and safe. Recipients showed an immune response against strains not included in the standard flu vaccine. http://www.israel21c.org/news/universal-flu-vaccine-testing-progresses/

Israel’s BiondVax has received FDA approval of its application to proceed with clinical trials of its universal Multimeric-001 flu vaccine (M-001). http://www.prnewswire.com/news-releases/biondvax-announces-fda-acceptance-of-ind-application-for-its-investigational-universal-flu-vaccine-507856431.html

The European Union and Japan have granted patents to the universal flu vaccine Multimeric-001 (M-001) developed by Israel’s BiondVax.  The ex-Weizmann Institute technology already has patents in the United States, Hong Kong, Australia, China, Russia and Mexico. http://www.timesofisrael.com/israels-universal-flu-vaccine-heads-for-universal-acceptance/

Israel’s BiondVax has just received a 4.87 million shekels grant from Israel’s Chief Scientist, to allow them continue development of their universal influenza vaccine M-001.  The treatment is in advanced trials and the funds will prepare it for commercialization. http://www.globes.co.il/en/article-chief-scientist-grants-biondvax-nis-487m-1000970349

Israeli biotech BiondVax announced that tests prove its universal flu vaccine matches all six pandemic strains in the world today. They include bird flu strains H5N1 and H7N9, which have spread to humans and killed hundreds of people. http://www.globes.co.il/serveen/globes/docview.asp?did=1000911070&fid=1725